Last updated: March 4, 2026
What Is NDC 59212-0240?
NDC 59212-0240 refers to a prescription drug product. Based on available public databases, this code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for spinal muscular atrophy (SMA) in pediatric patients under 2 years old.
Market Size and Demand Drivers
Patient Population
- SMA affects approximately 1 in 10,000 live births worldwide.
- Estimated treated population in the U.S. is approximately 1,200 to 2,000 infants annually under the age of 2.
- SMA severity varies; Type 1 SMA constitutes roughly 60% of cases.
Market Potential
| Parameter |
Estimate |
| Total SMA cases worldwide |
8,000 to 10,000 |
| U.S. pediatric SMA cases |
~1,500 |
| Treated patient estimate |
1,000 to 1,500 within the first five years of launch |
Competitive Landscape
- Other treatments include Spinraza (nusinersen) and Evrysdi (risdiplam).
- Zolgensma's one-time administration and potential for long-term disease modification confer distinct advantages.
- Adoption rates depend on FDA approvals, insurance coverage, and clinical guidelines.
Market Entry and Adoption Factors
- FDA approved in May 2019.
- Reimbursement approvals have expanded but vary by payer.
- Manufacturing complexity and high costs influence market access.
- AAV9 vector delivery system may restrict late-stage adoption due to supply constraints.
Price Projections
Current Pricing Status
- List Price: Approximately $2.125 million per dose (as of 2023).
- Cost structure involves one-time gene therapy with high upfront costs but potential long-term savings over chronic treatments.
Pricing Trends and Future Projections
| Year |
Estimated Price per Dose |
Rationale and Factors |
| 2023 |
$2.125 million |
Current list price; market stabilization phase |
| 2024 |
$2.10 million |
Slight decrease expected due to negotiations and increased competition |
| 2025 |
$2.05 million |
Entry of biosimilars or alternative gene therapies may influence pricing |
| 2026+ |
$2.00 million or lower |
Market maturation, manufacturing efficiencies, payer pressure |
Influencing Factors
- Manufacturing Improvements: Cost reductions through process optimization could lower prices.
- Reimbursement Policies: Payer negotiations and value-based agreements may decrease list prices.
- Market Competition: Development of next-generation gene therapies or biosimilars could compress prices.
- Global Expansion: High-income markets tend to adopt at list prices; emerging markets may see discounts.
Revenue Outlook
Assuming 1,200 treatments annually in the U.S. at $2.125 million:
| Year |
Estimated Revenue |
Total Patients Treated |
Comments |
| 2023 |
$2.55 billion |
1,200 |
Market uptake steady |
| 2024 |
$2.52 billion |
1,200 |
Price slightly reduced |
| 2025 |
$2.46 billion |
1,200 |
Additional market expansion |
Internationally, pricing varies; Europe may see discounts of 10-20%. Volume growth driven by expanding indications and new approvals could increase total revenue.
Risks to Valuation and Price
- Regulatory delays or safety concerns.
- Payer resistance or restrictions.
- Manufacturing bottlenecks limiting supply.
- Emergence of competing therapies.
Key Takeaways
- Market size for SMA treatment is constrained but significant, based on the small patient pool.
- Pricing remains high at current levels, with potential gradual reductions driven by market forces.
- Adoption depends on regulatory, reimbursement, and manufacturing factors.
- Revenue is projected to stabilize around $2.5 billion annually in mature markets, contingent on continued access and market expansion.
- Competition and biosimilar development pose future risks to pricing and market share.
FAQs
Q1. How long does the effect of Zolgensma last?
A1. Long-term durability studies are ongoing; early results indicate sustained benefit over several years, but ongoing surveillance is necessary.
Q2. What factors influence reimbursement negotiations?
A2. Clinical efficacy, manufacturing costs, pricing strategies, and health economics assessments impact payer decisions.
Q3. Can pricing decrease significantly in the next five years?
A3. Likely marginally due to market maturation, manufacturing efficiencies, and competition, but substantial reductions are uncertain.
Q4. Are biosimilars expected for Zolgensma?
A4. Biosimilar development is challenging due to gene therapy complexity; no biosimilars are commercially available yet.
Q5. What markets beyond the U.S. hold potential?
A5. Europe, Canada, and parts of Asia represent growing markets with regulatory pathways; pricing strategies will vary by country.
References
[1] Food and Drug Administration. (2019). FDA approves novel gene therapy to treat spinal muscular atrophy.
[2] Novartis. (2023). Zolgensma Prescribing Information.
[3] EvaluatePharma. (2023). Gene therapy market report.
[4] IQVIA. (2022). Worldwide prescription market forecasts.
[5] CMS.gov. (2023). Reimbursement policies for gene therapies.
